Prices delayed by at least 15 minutes | Print


Enanta Pharmaceuticals (ENTA)

Common Shares
Sell: $11.6|Buy: $19.93|Change: 0.93 (-7.12%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Address

500 Arsenal Street
Watertown
MA
USA
02472


Telephone

+1 617 607-0800


Sector 

Healthcare


Previous key dates

NameKey Date
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference2024-05-14T10:00:00
Enanta Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20242024-05-06T16:30:00
Enanta Pharmaceuticals Inc Second Quarter Earnings Result for 20242024-05-06T00:00:00
Leerink Partners Global Biopharma Conference 20242024-03-13T10:40:00
Enanta Pharmaceuticals Inc Annual General Meeting for 20242024-03-06T17:00:00
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-13T11:20:00
Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-13T11:20:00
Enanta Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-02-07T16:30:00
Enanta Pharmaceuticals Inc First Quarter Earnings Result for 20242024-02-07T00:00:00
Enanta Pharmaceuticals Inc Annual Report for 20232023-11-22T00:00:00
Enanta Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20232023-11-20T16:30:00
Enanta Pharmaceuticals Inc Fourth Quarter Earnings Result for 20232023-11-20T00:00:00
Respiratory Syncytial Virus: The Evolving Treatment Landscape2023-10-20T08:00:00
Enanta Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20232023-08-07T16:30:00
Enanta Pharmaceuticals Inc Third Quarter Earnings Result for 20232023-08-07T00:00:00
Jefferies Healthcare Conference2023-06-07T12:30:00
JMP Securities Life Sciences Conference2023-05-16T09:30:00
Enanta Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20232023-05-08T16:30:00
Enanta Pharmaceuticals Inc Second Quarter Earnings Result for 20232023-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.